<DOC>
	<DOC>NCT01842451</DOC>
	<brief_summary>A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Treatment-Naïve Adult Subjects With Genotype 1 Chronic Hepatitis C</brief_summary>
	<brief_title>A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>Subjects must have genotype 1 CHC and evidence of HCV infection at least 6 months before screening Subjects must be treatmentnaïve and have not received prior treatment with any interferon, immunomodulatory agent, or DAA for HCV Evidence of cirrhosis History or other clinical evidence of significant or unstable cardiac disease Any other cause of significant liver disease in addition to hepatitis C Creatinine clearance ≤50 mL/min using the CockcroftGault equation at screening Female subjects who are pregnant or nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>